Somavaratan - Aravive

Drug Profile

Somavaratan - Aravive

Alternative Names: hGH-rPEG - Aravive; hGH-XTEN; Human growth hormone-XTEN - Amunix; Recombinant human growth hormone long-acting - Aravive; Somatropin long-acting - Aravive; VRS-317

Latest Information Update: 23 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Versartis
  • Developer Aravive; Teijin Pharma
  • Class Growth hormones; Hormonal replacements; Recombinant fusion proteins
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 15 Oct 2018 Versartis has merged with Aravive Biologics to form Aravive
  • 24 Jun 2018 Biomarkers information updated
  • 07 Mar 2018 Versartis terminates the phase II/III VISTA extension trial as the primary endpoint of non-inferiority to daily therapy in the paediatric phase III study was not achieved for Somatotropin deficiency (In children) in USA, Belgium, Poland, Sweden (SC) (NCT02068521)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top